Risorgimento of Monkey Pox in 2022: A literature review from South East Asia

---

Review Article

Author Details : Pathan Multazim Muradkhan*, Nawaz Umar, Natasha Vaidya, Heeba Muradkhan Pathan, Sheeza Patel, Qamar Patel, Shahnawaz Mulani

Volume : 8, Issue : 3, Year : 2022

Article Page : 205-209

https://doi.org/10.18231/j.ijmmtd.2022.041

Suggest article by email

Get Permission

---

Abstract

India has confirmed its first monkeypox death case on 1 August 2022. Knowledge about its symptoms and spread is of outmost importance. With an incubation period of 6-13 days monkey pox distinctive symptom is lymphadenopathy. Close contacts are at the highest risk of contracting the disease and Polymerase chain reaction is the preferred laboratory test. This review article briefs on the important aspects of monkeypox disease including the measures taken by national and international agencies to spread awareness and steps taken to confine the spread of the disease. The article elaborates the role of ICMR New Delhi India and NIV Pune India in taking necessary actions to curtail the exposure of cases and the efforts taken in the invention of invitro diagnostic kits and providing resources for vaccine development.
Key message: This article attempts to describe the spread symptoms and measures taken by the competent authorities of The Government of India for immediate prevention, action and development of IVD kits and vaccination for monkeypox outbreak in the year 2022.
 
Keywords : Poxviridae, Outbreak, lymphadenopathy, Ticorivimat, ICMR, NIV

How to cite : Muradkhan P M, Umar N, Vaidya N, Pathan H M, Patel S, Patel Q, Mulani S, Risorgimento of Monkey Pox in 2022: A literature review from South East Asia. IP Int J Med Microbiol Trop Dis 2022;8(3):205-209

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.